CVS Health Corporation CVS SPX

Healthcare · Healthcare Plans · United States

https://www.cvshealth.com

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Market & Price

Market Cap

$116.08B

Current Price

$90.98

High / Low (52W)

$98.11 / $57.30

Beta

0.59

Valuation

Stock P/E

39.90

Industry PE

23.65

Forward P/E

10.88

PEG Ratio

0.26

Book Value

$60.84

Price to Book

1.50

P/S

0.29

EV/EBITDA

11.86

Dividend Yield

2.92%

Profitability & Returns

ROCE

3.19%

ROE

3.75%

ROA

2.67%

Profit Margin

0.72%

Op Margin

4.12%

EPS (Latest Qtr)

$2.30

EPS (TTM)

$2.28

Balance Sheet & Liquidity

Debt/Equity

1.01

Quick Ratio

0.61

Current Ratio

0.87

Debt

$78.35B

Total Assets

$253.54B

Current Assets

$74.71B

Working Capital

$-13.98B

Ownership

Promoter Holding

0.07%

Chg in Prom Hold

FII / Inst Holding

89.94%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$182.81B

Total Revenue (TTM)

$405.62B

EBITDA

$15.41B

Free Cash Flow

$5.20B

Operating Cash Flow

$10.33B

Shares Outstanding

1.28B

Gross Margin

13.39%

Payout Ratio

116.67%

Growth (CAGR)

Revenue 5Y

7.63%

Profit 5Y

-25.70%

Revenue (YoY)

6.10%

Earnings (YoY)

63.10%

PROS

Attractive dividend yield of 2.92%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -25.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CVS CVS Health Corporation SPX	90.98	39.90	$116.08B	2.92%	3.19%	3.75%	7.63%	-25.70%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	45.69B	46.71B	47.27B	-	61.40B	63.14B	64.55B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94.59B	98.92B	102.87B	105.69B	100.43B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80.19B	85.32B	89.06B	92.13B	84.80B
Gross Profit	6.40B	6.66B	7.30B	6.74B	7.01B	7.49B	7.61B	6.57B	6.93B	7.12B	7.90B	6.86B	7.20B	7.33B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.40B	13.59B	13.81B	13.57B	15.62B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.02B	11.21B	11.29B	11.46B	10.94B
Operating Income	2.26B	2.33B	2.73B	2.19B	2.36B	2.82B	3.00B	1.80B	2.12B	2.50B	3.11B	2.00B	-1.37B	2.57B	824.00M	2.69B	3.33B	2.93B	3.04B	3.46B	4.68B	3.25B	3.58B	4.33B	3.06B	3.54B	4.67B	-3.92B	3.45B	3.23B	3.69B	2.27B	3.04B	-	-	3.37B	2.38B	2.52B	2.11B	4.68B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.56B	3.58B	-1.56B	3.29B	5.83B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	785.00M	763.00M	784.00M	787.00M	774.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.62B	1.65B	-3.48B	1.35B	3.94B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	835.00M	634.00M	508.00M	-1.57B	981.00M
Net Income	1.27B	1.25B	1.50B	1.15B	924.00M	1.54B	1.71B	952.00M	1.10B	1.28B	3.29B	998.00M	-2.56B	1.39B	-419.00M	1.42B	1.94B	1.53B	1.75B	2.01B	2.98B	1.22B	2.22B	2.78B	1.60B	2.35B	3.03B	-3.41B	2.14B	1.90B	2.26B	1.11B	1.77B	-	-	1.78B	1.02B	-3.98B	2.94B	2.94B
Diluted EPS	1.12	1.11	1.34	1.04	0.86	1.43	1.59	0.92	1.07	1.26	3.22	0.98	-2.52	1.36	-0.37	1.09	1.49	1.17	1.33	1.53	2.26	0.93	1.68	2.10	1.20	1.77	2.29	-2.59	1.65	1.48	1.75	0.88	1.41	-	-	1.41	0.80	-3.13	2.30	2.30

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	177.53B	184.76B	193.92B	-	-	-	322.47B	357.78B	372.81B	402.07B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	267.96B	303.35B	321.41B	346.70B
Gross Profit	16.11B	18.29B	20.36B	20.22B	20.56B	22.49B	23.78B	25.37B	26.53B	28.86B	28.55B	-	-	-	-	54.50B	54.43B	51.40B	55.36B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.21B	39.83B	41.71B	44.98B
Operating Income	4.79B	6.05B	6.42B	6.14B	6.33B	7.21B	8.04B	8.80B	9.47B	10.39B	9.54B	4.02B	11.99B	13.91B	-	16.29B	14.60B	9.70B	10.38B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.35B	18.20B	13.70B	9.86B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.29B	2.66B	2.96B	3.12B
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.84B	11.17B	6.15B	2.14B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51B	2.81B	1.56B	408.00M
Net Income	2.64B	3.20B	3.70B	3.43B	-	-	-	4.64B	5.24B	5.32B	6.62B	-594.00M	6.63B	7.18B	-	4.31B	8.34B	4.61B	1.77B
Diluted EPS	1.92	2.18	2.55	2.49	2.57	3.02	3.74	3.96	4.63	4.90	6.44	-0.57	5.08	5.46	-	3.26	6.47	3.66	1.39

Compounded Sales Growth

5 Years:	7.63%
1 Year:	6.10%

Compounded Profit Growth

5 Years:	-25.70%
1 Year:	63.10%

Stock Price Performance

1 Year:	+47.26%
6 Months:	+17.92%
3 Months:	+14.87%
1 Month:	+8.44%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	60.96B	61.64B	62.17B	64.85B	66.22B	71.53B	74.19B	92.44B	94.46B	95.13B	196.46B	216.67B	222.45B	230.72B	-	228.28B	249.73B	253.22B	253.54B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65.63B	67.86B	68.64B	74.71B
Cash & Equivalents	530.00M	1.06B	1.35B	1.09B	1.43B	1.41B	1.38B	4.09B	2.48B	2.46B	3.37B	1.70B	4.06B	-	5.68B	7.85B	-	12.95B	8.20B	8.59B	8.45B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.09B	18.02B	18.11B	19.25B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.66B	15.62B	14.61B	16.32B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	57.44B	137.91B	157.95B	158.28B	161.01B	-	156.51B	173.09B	177.49B	178.16B
Current Liabilities	-	-	13.49B	12.30B	11.07B	11.96B	14.15B	15.43B	19.03B	23.17B	26.25B	30.65B	44.01B	45.76B	53.30B	62.02B	-	69.42B	79.19B	84.61B	88.69B
Long Term Debt	-	-	8.06B	8.76B	8.65B	9.21B	9.13B	12.84B	11.63B	26.27B	25.61B	22.18B	71.44B	71.35B	-	-	-	50.48B	58.64B	60.53B	60.50B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.73B	79.39B	82.92B	79.95B
Total Equity	-	31.32B	34.57B	35.77B	37.70B	-	37.65B	37.94B	37.96B	37.20B	36.83B	37.69B	58.23B	58.40B	63.86B	69.39B	-	71.47B	76.46B	75.56B	75.21B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.76B	1.77B	1.78B	1.79B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	3.23B	3.95B	4.04B	4.78B	5.86B	6.67B	5.78B	8.14B	8.54B	10.14B	8.01B	8.87B	12.85B	15.87B	-	16.18B	13.43B	9.11B	10.64B
Investing Cash Flow	-3.08B	-4.58B	-1.07B	-1.64B	-2.41B	-1.85B	-1.83B	-4.04B	-13.42B	-2.47B	-2.88B	-43.28B	-3.34B	-5.53B	-	-5.05B	-20.89B	-7.61B	-5.87B
Financing Cash Flow	378.00M	929.00M	-3.23B	-2.80B	-3.46B	-4.86B	-1.24B	-5.69B	4.88B	-6.76B	-6.75B	36.82B	-7.65B	-7.70B	-	-10.52B	2.68B	-1.14B	-4.94B
Capital Expenditure	-1.80B	-2.18B	-2.55B	-2.00B	-1.87B	-2.03B	-1.98B	-2.14B	-2.37B	-2.22B	-1.92B	-2.04B	-2.46B	-2.44B	-	-2.73B	-3.03B	-2.78B	-2.83B
Free Cash Flow	1.43B	1.77B	1.49B	2.77B	3.98B	4.64B	3.80B	6.00B	6.17B	7.92B	6.09B	6.83B	10.39B	13.43B	-	13.45B	10.39B	6.33B	7.81B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	614.00M	-4.78B	359.00M	-172.00M
Share Buybacks	5.37B	23.00M	2.48B	1.50B	3.00B	4.33B	3.98B	4.00B	5.00B	4.46B	4.36B	0	0	0	0	3.50B	2.01B	3.02B	0
Dividends Paid	323.00M	383.00M	439.00M	479.00M	674.00M	829.00M	1.10B	1.29B	1.58B	1.84B	2.05B	2.04B	2.60B	2.62B	2.62B	2.91B	3.13B	3.37B	3.40B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	16.3%	15.4%	-	-	-	-	16.9%	15.2%	13.8%	13.8%
Operating Margin %	-	-	-	-	-	-	-	-	-	5.9%	5.2%	2.1%	-	-	-	5.1%	4.1%	2.6%	2.6%
Net Margin %	-	-	-	-	-	-	-	-	-	3.0%	3.6%	-0.3%	-	-	-	1.3%	2.3%	1.2%	0.4%
ROE %	8.4%	9.2%	10.3%	9.1%	-	-	-	12.2%	14.1%	14.4%	17.6%	-1.0%	10.4%	10.3%	-	6.0%	10.9%	6.1%	2.4%
ROCE %	-	12.7%	13.0%	12.0%	12.0%	13.8%	14.3%	16.0%	13.7%	15.2%	14.8%	2.6%	7.1%	8.2%	-	10.3%	8.6%	5.8%	6.3%

Shareholding Pattern

Insiders

0.07%

Institutions

89.94%

Public Float

90.00%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.87%	125.92M	$11.46B
2	Vanguard Capital Management LLC	6.48%	82.65M	$7.52B
3	Capital World Investors	6.05%	77.25M	$7.03B
4	State Street Corporation	4.65%	59.32M	$5.40B
5	Dodge & Cox Inc.	4.06%	51.78M	$4.71B
6	FMR, LLC	2.45%	31.20M	$2.84B
7	JPMORGAN CHASE & CO	2.31%	29.53M	$2.69B
8	Geode Capital Management, LLC	2.31%	29.46M	$2.68B
9	Vanguard Portfolio Management LLC	2.04%	26.00M	$2.37B
10	Invesco Ltd.	1.97%	25.14M	$2.29B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CVS

CNBC Business hu, 28 May 2026

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

CVS · Healthcare